High-mannose glycans are elevated during breast cancer progression

Maria Lorna A De Leoz, Lawrence J T Young, Hyun Joo An, Scott R. Kronewitter, Jaehan Kim, Suzanne Miyamoto, Alexander D Borowsky, Helen K Chew, Carlito B Lebrilla

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

Alteration in glycosylation has been observed in cancer. However, monitoring glycosylation changes during breast cancer progression is difficult in humans. In this study, we used a well-characterized transplantable breast tumor mouse model, the mouse mammary tumor virus-polyoma middle T antigen, to observe early changes in glycosylation. We have previously used the said mouse model to look at O-linked glycosylation changes with breast cancer. In this glycan biomarker discovery study, we examined N-linked glycan variations during breast cancer progression of the mouse model but this time doubling the number of mice and blood draw points. N-glycans from total mouse serum glycoproteins were profiled using matrix-assisted laser desorption/ionization Fourier transform-ion cyclotron resonance mass spectrometry at the onset, progression, and removal of mammary tumors. We observed four N-linked glycans, m/z 1339.480 (Hex3HexNAc), 1485.530 (Hex3HexNAc4Fuc), 1809.639 (Hex5HexNAc4Fuc), and 1905.630 (Man9), change in intensity in the cancer group but not in the control group. In a separate study, N-glycans from total human serum glycoproteins of breast cancer patients and controls were also profiled. Analysis of human sera using an internal standard showed the alteration of the low-abundant high-mannose glycans, m/z 1419.475, 1581.528, 1743.581, 1905.634 (Man6-9), in breast cancer patients. A key observation was the elevation of a high-mannose type glycan containing nine mannoses, Man9, m/z 1905.630 in both mouse and human sera in the presence of breast cancer, suggesting an incompletion of the glycosylation process that normally trims back Man 9 to produce complex and hybrid type oligosaccharides.

Original languageEnglish (US)
JournalMolecular and Cellular Proteomics
Volume10
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Mannose
Glycosylation
Polysaccharides
Breast Neoplasms
Tumors
Serum
Glycoproteins
Cyclotron resonance
Mouse mammary tumor virus
Cyclotrons
Viral Tumor Antigens
Biomarkers
Oligosaccharides
Viruses
Fourier Analysis
Ionization
Mass spectrometry
Desorption
Fourier transforms
Blood

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Analytical Chemistry
  • Medicine(all)

Cite this

De Leoz, M. L. A., Young, L. J. T., An, H. J., Kronewitter, S. R., Kim, J., Miyamoto, S., ... Lebrilla, C. B. (2011). High-mannose glycans are elevated during breast cancer progression. Molecular and Cellular Proteomics, 10(1). https://doi.org/10.1074/mcp.M110.002717-1

High-mannose glycans are elevated during breast cancer progression. / De Leoz, Maria Lorna A; Young, Lawrence J T; An, Hyun Joo; Kronewitter, Scott R.; Kim, Jaehan; Miyamoto, Suzanne; Borowsky, Alexander D; Chew, Helen K; Lebrilla, Carlito B.

In: Molecular and Cellular Proteomics, Vol. 10, No. 1, 01.2011.

Research output: Contribution to journalArticle

De Leoz, MLA, Young, LJT, An, HJ, Kronewitter, SR, Kim, J, Miyamoto, S, Borowsky, AD, Chew, HK & Lebrilla, CB 2011, 'High-mannose glycans are elevated during breast cancer progression', Molecular and Cellular Proteomics, vol. 10, no. 1. https://doi.org/10.1074/mcp.M110.002717-1
De Leoz, Maria Lorna A ; Young, Lawrence J T ; An, Hyun Joo ; Kronewitter, Scott R. ; Kim, Jaehan ; Miyamoto, Suzanne ; Borowsky, Alexander D ; Chew, Helen K ; Lebrilla, Carlito B. / High-mannose glycans are elevated during breast cancer progression. In: Molecular and Cellular Proteomics. 2011 ; Vol. 10, No. 1.
@article{f04caa757a1945d4bdb018f626b997c8,
title = "High-mannose glycans are elevated during breast cancer progression",
abstract = "Alteration in glycosylation has been observed in cancer. However, monitoring glycosylation changes during breast cancer progression is difficult in humans. In this study, we used a well-characterized transplantable breast tumor mouse model, the mouse mammary tumor virus-polyoma middle T antigen, to observe early changes in glycosylation. We have previously used the said mouse model to look at O-linked glycosylation changes with breast cancer. In this glycan biomarker discovery study, we examined N-linked glycan variations during breast cancer progression of the mouse model but this time doubling the number of mice and blood draw points. N-glycans from total mouse serum glycoproteins were profiled using matrix-assisted laser desorption/ionization Fourier transform-ion cyclotron resonance mass spectrometry at the onset, progression, and removal of mammary tumors. We observed four N-linked glycans, m/z 1339.480 (Hex3HexNAc), 1485.530 (Hex3HexNAc4Fuc), 1809.639 (Hex5HexNAc4Fuc), and 1905.630 (Man9), change in intensity in the cancer group but not in the control group. In a separate study, N-glycans from total human serum glycoproteins of breast cancer patients and controls were also profiled. Analysis of human sera using an internal standard showed the alteration of the low-abundant high-mannose glycans, m/z 1419.475, 1581.528, 1743.581, 1905.634 (Man6-9), in breast cancer patients. A key observation was the elevation of a high-mannose type glycan containing nine mannoses, Man9, m/z 1905.630 in both mouse and human sera in the presence of breast cancer, suggesting an incompletion of the glycosylation process that normally trims back Man 9 to produce complex and hybrid type oligosaccharides.",
author = "{De Leoz}, {Maria Lorna A} and Young, {Lawrence J T} and An, {Hyun Joo} and Kronewitter, {Scott R.} and Jaehan Kim and Suzanne Miyamoto and Borowsky, {Alexander D} and Chew, {Helen K} and Lebrilla, {Carlito B}",
year = "2011",
month = "1",
doi = "10.1074/mcp.M110.002717-1",
language = "English (US)",
volume = "10",
journal = "Molecular and Cellular Proteomics",
issn = "1535-9476",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "1",

}

TY - JOUR

T1 - High-mannose glycans are elevated during breast cancer progression

AU - De Leoz, Maria Lorna A

AU - Young, Lawrence J T

AU - An, Hyun Joo

AU - Kronewitter, Scott R.

AU - Kim, Jaehan

AU - Miyamoto, Suzanne

AU - Borowsky, Alexander D

AU - Chew, Helen K

AU - Lebrilla, Carlito B

PY - 2011/1

Y1 - 2011/1

N2 - Alteration in glycosylation has been observed in cancer. However, monitoring glycosylation changes during breast cancer progression is difficult in humans. In this study, we used a well-characterized transplantable breast tumor mouse model, the mouse mammary tumor virus-polyoma middle T antigen, to observe early changes in glycosylation. We have previously used the said mouse model to look at O-linked glycosylation changes with breast cancer. In this glycan biomarker discovery study, we examined N-linked glycan variations during breast cancer progression of the mouse model but this time doubling the number of mice and blood draw points. N-glycans from total mouse serum glycoproteins were profiled using matrix-assisted laser desorption/ionization Fourier transform-ion cyclotron resonance mass spectrometry at the onset, progression, and removal of mammary tumors. We observed four N-linked glycans, m/z 1339.480 (Hex3HexNAc), 1485.530 (Hex3HexNAc4Fuc), 1809.639 (Hex5HexNAc4Fuc), and 1905.630 (Man9), change in intensity in the cancer group but not in the control group. In a separate study, N-glycans from total human serum glycoproteins of breast cancer patients and controls were also profiled. Analysis of human sera using an internal standard showed the alteration of the low-abundant high-mannose glycans, m/z 1419.475, 1581.528, 1743.581, 1905.634 (Man6-9), in breast cancer patients. A key observation was the elevation of a high-mannose type glycan containing nine mannoses, Man9, m/z 1905.630 in both mouse and human sera in the presence of breast cancer, suggesting an incompletion of the glycosylation process that normally trims back Man 9 to produce complex and hybrid type oligosaccharides.

AB - Alteration in glycosylation has been observed in cancer. However, monitoring glycosylation changes during breast cancer progression is difficult in humans. In this study, we used a well-characterized transplantable breast tumor mouse model, the mouse mammary tumor virus-polyoma middle T antigen, to observe early changes in glycosylation. We have previously used the said mouse model to look at O-linked glycosylation changes with breast cancer. In this glycan biomarker discovery study, we examined N-linked glycan variations during breast cancer progression of the mouse model but this time doubling the number of mice and blood draw points. N-glycans from total mouse serum glycoproteins were profiled using matrix-assisted laser desorption/ionization Fourier transform-ion cyclotron resonance mass spectrometry at the onset, progression, and removal of mammary tumors. We observed four N-linked glycans, m/z 1339.480 (Hex3HexNAc), 1485.530 (Hex3HexNAc4Fuc), 1809.639 (Hex5HexNAc4Fuc), and 1905.630 (Man9), change in intensity in the cancer group but not in the control group. In a separate study, N-glycans from total human serum glycoproteins of breast cancer patients and controls were also profiled. Analysis of human sera using an internal standard showed the alteration of the low-abundant high-mannose glycans, m/z 1419.475, 1581.528, 1743.581, 1905.634 (Man6-9), in breast cancer patients. A key observation was the elevation of a high-mannose type glycan containing nine mannoses, Man9, m/z 1905.630 in both mouse and human sera in the presence of breast cancer, suggesting an incompletion of the glycosylation process that normally trims back Man 9 to produce complex and hybrid type oligosaccharides.

UR - http://www.scopus.com/inward/record.url?scp=78651063463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651063463&partnerID=8YFLogxK

U2 - 10.1074/mcp.M110.002717-1

DO - 10.1074/mcp.M110.002717-1

M3 - Article

VL - 10

JO - Molecular and Cellular Proteomics

JF - Molecular and Cellular Proteomics

SN - 1535-9476

IS - 1

ER -